ES2647070T3 - Vacunas para tuberculosis que comprenden antígenos expresados durante la fase de infección latente - Google Patents

Vacunas para tuberculosis que comprenden antígenos expresados durante la fase de infección latente Download PDF

Info

Publication number
ES2647070T3
ES2647070T3 ES09172905.3T ES09172905T ES2647070T3 ES 2647070 T3 ES2647070 T3 ES 2647070T3 ES 09172905 T ES09172905 T ES 09172905T ES 2647070 T3 ES2647070 T3 ES 2647070T3
Authority
ES
Spain
Prior art keywords
mice
rv2660c
vaccine
tuberculosis
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09172905.3T
Other languages
English (en)
Spanish (es)
Inventor
Carina Vingsbo-Lundberg
Claus Aagaard
Peter Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut
Original Assignee
Statens Serum Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut filed Critical Statens Serum Institut
Application granted granted Critical
Publication of ES2647070T3 publication Critical patent/ES2647070T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09172905.3T 2005-06-23 2006-06-20 Vacunas para tuberculosis que comprenden antígenos expresados durante la fase de infección latente Expired - Lifetime ES2647070T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK200500924 2005-06-23
DKPA200500924 2005-06-23
DK200501393 2005-10-05
DKPA200501393 2005-10-05

Publications (1)

Publication Number Publication Date
ES2647070T3 true ES2647070T3 (es) 2017-12-19

Family

ID=37134239

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09172905.3T Expired - Lifetime ES2647070T3 (es) 2005-06-23 2006-06-20 Vacunas para tuberculosis que comprenden antígenos expresados durante la fase de infección latente

Country Status (12)

Country Link
US (4) US7968105B2 (enExample)
EP (4) EP2163255B1 (enExample)
JP (2) JP5219808B2 (enExample)
KR (2) KR101188045B1 (enExample)
CN (1) CN102836425B (enExample)
AU (1) AU2006261445B2 (enExample)
BR (1) BRPI0612833A2 (enExample)
CA (2) CA2612900C (enExample)
ES (1) ES2647070T3 (enExample)
IL (3) IL188222A (enExample)
MX (1) MX2007016165A (enExample)
WO (1) WO2006136162A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529931C1 (de) 1995-08-02 1997-04-03 Mannesmann Ag Plattenkokille zur Erzeugung von Strängen aus Stahl
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2008124647A2 (en) * 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
JP5713672B2 (ja) * 2007-04-12 2015-05-07 ジェニファー ライター， 結核のワクチンおよびその使用方法
AU2008271756B2 (en) * 2007-06-29 2012-10-04 Statens Serum Institut The use of monomycolyl glycerol (MMG) as an adjuvant
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2315773B1 (en) 2008-07-25 2016-08-24 GlaxoSmithKline Biologicals S.A. Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
AU2010232180B2 (en) * 2009-03-31 2016-09-22 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
US20120201846A1 (en) * 2009-07-29 2012-08-09 Bernd Helmut Adam Rehm Polymer particles and uses thereof
SG11201500171YA (en) * 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
RU2520737C1 (ru) * 2013-04-25 2014-06-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА pESAT6-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-DBD, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК ESAT6-DBD И ИХ ПРИМЕНЕНИЕ
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
RU2539026C1 (ru) * 2013-06-11 2015-01-10 Федеральное государственное бюджетное учреждение "Центральный научно-исследовательский институт туберкулеза" Российской академии медицинских наук РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-CFP10-DBD, РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], СПОСОБ ПОЛУЧЕНИЯ, ИММОБИЛИЗАЦИИ, КОНЦЕНТРИРОВАНИЯ И ОЧИСТКИ РЕКОМБИНАНТНОГО БЕЛКА ESAT6-CFP10-DBD НА ДЕКСТРАНЕ, РЕКОМБИНАНТНЫЙ БЕЛОК ESAT6-CFP10-DBD И ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК ESAT6-CFP10-DBD
EP3013364B1 (en) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
EP3092000A1 (en) * 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
CN107970444B (zh) * 2016-10-25 2022-03-01 中国人民解放军第三0九医院 复合佐剂及含有该复合佐剂的疫苗
WO2020249756A1 (en) 2019-06-14 2020-12-17 Statens Serum Institut Fusion proteins for tuberculosis vaccines
CA3196596A1 (en) * 2020-09-23 2022-03-31 The General Hospital Corporation Bcg vaccinations for prevention of covid-19 and other infectious diseases
KR102709729B1 (ko) * 2020-12-04 2024-09-25 주식회사 제넥신 결핵의 예방 또는 치료용 약학적 조성물
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
CN118765203A (zh) 2022-02-21 2024-10-11 史坦恩斯血清研究所 一种新型阳离子佐剂组合物
CN117531001A (zh) * 2023-11-15 2024-02-09 首都医科大学附属北京胸科医院 结核分枝杆菌毒素抗毒素系统及其相关应用
CN117683144A (zh) * 2023-12-08 2024-03-12 上海市公共卫生临床中心 一种结核分支杆菌融合抗原及其亚单位疫苗
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1331C (da) 1897-11-15 Hans Daae Militær- og Skilygte.
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
CN100365017C (zh) * 1994-09-20 2008-01-30 日立化成工业株式会社 肺炎衣原体抗原多肽
JP4091112B2 (ja) 1995-06-07 2008-05-28 コノート ラボラトリーズ インコーポレーテッド リポタンパク質の発現
US20040018574A1 (en) 1998-08-25 2004-01-29 Marcel Behr Molecular differences between species of the M. tuberculosis complex
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
WO2002004018A2 (en) 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
CA2445179A1 (en) * 2001-04-23 2002-10-31 Elitra Pharmaceuticals, Inc. Identification of essential genes of aspegillus fumigatus and methods of use
US7393540B2 (en) * 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines

Also Published As

Publication number Publication date
MX2007016165A (es) 2008-03-14
US20120114687A1 (en) 2012-05-10
US8703151B2 (en) 2014-04-22
AU2006261445A1 (en) 2006-12-28
US8101193B2 (en) 2012-01-24
EP2380590A2 (en) 2011-10-26
CN102836425A (zh) 2012-12-26
CA2612900C (en) 2016-08-09
US8293250B2 (en) 2012-10-23
EP2380589A2 (en) 2011-10-26
IL222914A0 (en) 2012-12-31
KR101188045B1 (ko) 2012-10-05
CA2836319A1 (en) 2006-12-28
JP5219808B2 (ja) 2013-06-26
IL222915A0 (en) 2012-12-31
KR20080027877A (ko) 2008-03-28
KR101035053B1 (ko) 2011-05-19
US7968105B2 (en) 2011-06-28
HK1179855A1 (zh) 2013-10-11
AU2006261445B2 (en) 2011-03-31
IL188222A (en) 2015-11-30
US20090186048A1 (en) 2009-07-23
CA2612900A1 (en) 2006-12-28
BRPI0612833A2 (pt) 2010-11-30
EP1910409A2 (en) 2008-04-16
CN102836425B (zh) 2015-08-19
WO2006136162A3 (en) 2007-11-15
EP2380589A3 (en) 2012-09-12
US20110206713A1 (en) 2011-08-25
WO2006136162A2 (en) 2006-12-28
EP2380590A3 (en) 2012-08-22
IL188222A0 (en) 2008-03-20
EP2163255A1 (en) 2010-03-17
JP2013121959A (ja) 2013-06-20
EP2163255B1 (en) 2017-08-09
JP2008543890A (ja) 2008-12-04
HK1124071A1 (en) 2009-07-03
KR20100122130A (ko) 2010-11-19
US20130095132A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
US8703151B2 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
US10519202B2 (en) Tuberculosis TB vaccine to prevent reactivation
USRE46583E1 (en) Vaccines comprising TB10.4
US10010595B2 (en) Live recombinant booster vaccine against tuberculosis
WO2005061534A2 (en) Improved tuberculosis vaccines
CN101248084B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
AU2013206297A1 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1124071B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1179855B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase